Friday, June 03, 2022 3:34:59 PM
this is temporary AND WAS DISCUSSED in the last CC at the 8:35 minute mark. I’ll paste link to recording for reference .. specifically noted this may occur temporarily… and is explained .. click on link provide your email etc then use the passcode provided below to be able to watch the recording … you can fast forward to the time to if only wanting to hear a snippet at a time
At 8:35 “temporary”
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Listen to the CC at this time portion for explanation:
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
Here’s some other key time stops to get clarity for frequently asked questions :
4:45 start time
6:20 begin investors Q&A
7:00 SEC discussed
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
8:56 Farmatsevtik Armenia
13:40 QNTA Main GOALS & PLANS
17:35 paxlovid relapse unlike escozine symptoms did not return
18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal”
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient lung exray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine (lots of very good information easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
33:30 COVID registration PROCESS versus CANCER Registration process
35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP )
36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study
37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again)
38:06 FDA strategy summarized
“Actively working to completely FDA process”
Funding discussed to finished indoor facility in DR
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
43:08 a vision for DISTRIBUTION and New Opportunities
46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned
49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
51:56 name & SYMBOL CHANGE addressed
52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood)
53:57 Shared CEO position defined
Activitie negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company to NASDAQ
roles of co ceo positions discussed
55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind #
56:45 dispels myth of his salary
57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination research to where qnta is now and moving forward on a continued path in a achieving goals
***
As always, one should do DD
Listen to the CC. Read the data etc
GLTA
***
Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
At 8:35 “temporary”
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Listen to the CC at this time portion for explanation:
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
Here’s some other key time stops to get clarity for frequently asked questions :
4:45 start time
6:20 begin investors Q&A
7:00 SEC discussed
7:31 Auditor change / 8k item 4.01 discussed
813 OTC OTCQB discussed
8:56 Farmatsevtik Armenia
13:40 QNTA Main GOALS & PLANS
17:35 paxlovid relapse unlike escozine symptoms did not return
18:35 PROVISIONAL PATENT now “ABLE TO SHARE PUBLICLY” escozine Covid 19 therapy “important goal”
20:22 CHART escozine therapy results EFFICACY charts
21:36 patient lung exray showing ASTOUNDING RESULTS from MONOTHERAPY escozine
22:54 Chief Scientific Officer Dr Matalka breaks down escozine (lots of very good information easy to follow slides - science of escozine explained very well *** worth listening / watching this portion, great visuals and easy to understand science of how Escozine works against Covid
26:36 *** [ “polarization of escozine significantly increased cox-2 inhibition in comparison with non polarized venom”]
31:38 slide shown Escozine BLOCKS omicron
32:50 “beauty of Escozine”
33:30 COVID registration PROCESS versus CANCER Registration process
35:05 delay in Dominican Republic studies explained (** worth noting, ANY medical trial is at the mercy of available subjects that fit in a specified sub group etc .. Covid rates WERE down … NOW going back UP )
36:37 currently Mexico has ENOUGH patients for DOUBLE BLIND study
37:13 Mexico EXPORT certificate (explains easier to import from US to Mexico .. double blind test mentioned again)
38:06 FDA strategy summarized
“Actively working to completely FDA process”
Funding discussed to finished indoor facility in DR
41:25 Dilution discussed ** last stage of closing with investors attorney to “avoid future dilution” ***
42:00 investor engaging with FDA LOBBYIST to help FDA process
** investor has experience w distribution of Covid 19 vaccines
42:43 FDA status - discussed “second potential investor” - help to move application from pre Ind to Ind status
43:08 a vision for DISTRIBUTION and New Opportunities
46:25 WALGREENS dialogue .. speaker has “experience in retail space for 30 years” … meeting with WALGREENS mentioned
49:28 Kevin Harrington (spelling??) Group REACHED out To QNTA expressing interest in Representing them - product samples to be shipped
50:00-51:54 *LICENSING discussed*
(noted / reminder in the CC big pharma moves slow / process takes time)
51:56 name & SYMBOL CHANGE addressed
52:45 VENDING MACHINE lease discussed - modern style with visual screens for product video (ability to have video screen on the machine itself is what I understood)
53:57 Shared CEO position defined
Activitie negotiations for CEO position, third round of interviews completed - CANDIDATE has extensive biotech experience & EXPERIENCE in taking Otc company to NASDAQ
roles of co ceo positions discussed
55:50 addressed the PRE IND # and shows slide with direct communication with FDA showing the validity of the pre Ind #
56:45 dispels myth of his salary
57:25 “life’s work” *** worth hearing this portion, imo, shows a testimony and drive of the culmination research to where qnta is now and moving forward on a continued path in a achieving goals
***
As always, one should do DD
Listen to the CC. Read the data etc
GLTA
***
Cc link and code link below;
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Date: May 12, 2022 04:52 PM Eastern Time (US and Canada)
Meeting Recording:
https://us06web.zoom.us/rec/share/bLPZGqeBj6t9ecgZBactMfKt6KOPXZ1Q5qYKn0z5KhawBW_vmc7JFeJNtPhjq0wk.gl8CdDheQtl33mSC
Access Passcode: $uPi^+4r
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.